Small Pharma Completes Enrollment In Phase IIa DMT-Assisted Psychotherapy Clinical Trial In Patients With Major Depressive Disorder
Dosing for primary endpoint now complete.
Small Pharma Enters Into Automatic Share Purchase Plan
LONDON, September 13, 2022 (GLOBE NEWSWIRE) – Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the…
Small Pharma Announces TSXV Approval of Normal Course Issuer Bid
The TSX Venture Exchange has accepted Small Pharma's application.
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
Study will explore the interaction between SSRI antidepressants and SPL026.
Canadian Patent Grant Strengthens Small Pharma’s International Position
Further Composition of Matter protection for SPL028.
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy with Injectable Formulation
U.S. Patent Grant To Strengthen Small Pharma’s Dmt Patent Strategy With Injectable Formulation.
George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer
George Tziras to succeed Peter Rands as Small Pharma Chief Executive Officer, with Peter Rands…
Small Pharma Reports Fiscal First Quarter 2023 Highlights
Small Pharma reports fiscal first quarter 2023 highlights, as progress continues with multiple trials expected…
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022
Small Pharma reports highlights for the fiscal year ended February 2022, including its financial results.
Small Pharma Shares Business Update Ahead of Annual Financial Results
Small Pharma shares business update ahead of annual financial results, including a new COO appointment.